Initial Experience and Clinical Application of Gadoterate Meglumine in Abbreviated DCE-MRI of the Breast with Ultrafast Imaging.

Motivation: There is increasing interest in high temporal resolution imaging techniques in MRI breast for cancer detection. Goal(s): Our goal was to evaluate clinical application of Gadoterate Meglumine in abbreviated DCE-MRI breast for cancer detection, focusing on quantitative analysis with ultrafast imaging. Approach: We calculated quantitative pharmacokinetic parameters from ultrafast imaging for breast cancer detection. Results: Ktrans had the highest diagnostic sensitivity (98.3% [95% CI: 91.1-100; p-value < 0.05]). A, A* α, AUC30 (initial area under contrast enhancement versus time curve over 30 seconds), and Ktrans have excellent power for cancer detection, with areas under ROC of 0.955, 0.962, 0.963, and 0.938, respectively. Impact: Ultrafast imaging (3.5-4.6 seconds) yields benefit individuals with preserved diagnostic accuracy for breast cancer detection. Furthermore, lower signal enhancement of background parenchyma by using gadoterate meglumine may help for lesion detection in screening settings, particularly in young or premenopausal women.